Edgewise gets FDA Fast Track Designation for EDG-5506 to treat Duchenne
The FDA has also granted Rare Pediatric Disease Designation for the treatment of Duchenne, Fast Track designation for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Feb 24
The FDA has also granted Rare Pediatric Disease Designation for the treatment of Duchenne, Fast Track designation for…
14 Feb 24
Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s…
13 Feb 24
The FDA approval was based on efficacy and safety findings from two multicentre, randomised, double-blind, parallel-group, placebo-controlled 12-week…
13 Feb 24
The EC approval was driven by the efficacy and safety data from the placebo-controlled MOXIe Part 2 study…
13 Feb 24
Designation underscores the unmet need for medicines that can achieve functional cure in patients with chronic hepatitis B…
13 Feb 24
ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative across multiple solid tumors and hematologic…
12 Feb 24
The breakthrough therapy designation was based on results from the proof-of-concept Phase 2 open-label UNITY clinical trial in…
12 Feb 24
HMB-001 is designed to bind and stabilise endogenous Factor VIIa using one antibody arm, while the second arm…
12 Feb 24
DISC-3405 is an investigational, anti-TMPRSS6 monoclonal antibody designed to increase hepcidin production and suppress serum iron
08 Feb 24
Under the terms of the deal, Jazz will secure all rights, patents, title, and interest in exchange for…